Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone

European Journal of Pharmacology

Volumn 365, Issue 2-3, 1999, Pages 301-308

  Rieger, Johannes ^a   Durka, Silke ^a   Streffer, Johannes ^a   Dichgans, Johannes ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

BCL 2 (B cell lymphoma 2); Chemotherapy; Dexamethasone; Gemcitabine; Glioma, malignant

Indexed keywords

ACETYLCYSTEINE; CYTARABINE; DEXAMETHASONE; GEMCITABINE; N TERT BUTYL ALPHA PHENYLNITRONE; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BACTERIUM CULTURE; CELL CULTURE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTIOXIDANTS; CELL SURVIVAL; DEOXYCYTIDINE; DEXAMETHASONE; DRUG INTERACTIONS; GENES, P53; GLIOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032910182     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00883-8     Document Type: Article

References (27)

1. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
2. Arning M., Blatter J. Gemcitabine in solid tumors. Present status and future development. Onkologie. 20:1997;297-304.
3. Bouffard D.Y., Momparler R.L. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk. Res. 19:1995;849-856.
4. Bouffard D.Y., Momparler L.F., Momparler R.L. Comparison of antineoplastic activity of 2′,2′-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs. 2:1991;49-55.
5. Cronauer M.V., Klocker H., Talasz H., Geisen F.H., Hobisch A., Radmayr C., Böck G., Culig Z., Schirmer M., Reissigl A., Bartsch G., Konwalinka G. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate. 28:1996;172-181.
6. Csoka K., Liliemark J., Larsson R., Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin. Oncol. 22:1995;47-53. Suppl. 11.
7. Esumi Y., Mitsugi K., Takao A., Seki H., Kawai M. Disposition of gemcitabine in rat and dog after single and multiple dosings. Xenobiotica. 8:1994;805-817.
8. Gandhi V., Legha J., Chen F., Hertel L.W., Plunkett W. Excision of 2′,2′-difluorodeoycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 56:1996;4453-4459.
9. Gruber J., Geisen F., Sgonc R., Egle A., Villunger A., Boeck G., Konwalinka G., Greil R. 2′,2′-Diflourodeoxycytidine (gemcitabine) induces apoptosis in myelome cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Stem Cells. 14:1996;351-362.
10. Guchelaar H.J., Richel D.J., Van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat. Rev. 22:1996;15-31.
11. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 38:1990;567-572.
12. Heinemann V., Schulz L., Issels R.D., Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin. Oncol. 22:1995;11-18. (Suppl. 1).
13. WAF/CIP1 protein accumulation. Oncogene. 17:1998;1567-1575.
14. Noble S., Goa K.L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 54:1997;447-472.
15. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22:1995;3-10.
16. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
17. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., Vermorken J.B., Pinedo H.M., Peters G.J. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54:1994;4138-4143.
18. Schulz J.B., Bremen D., Reed J.C., Lommatzsch J., Takayama S., Wüllner U., Löschmann P.A., Klockgether T., Weller M. Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. J. Neurochem. 69:1997;2075-2086.
19. Shewach D.S., Lawrence T.S. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin. Oncol. 22:1995;68-71.
20. Shewach D.S., Hahn T.M., Chang E., Hertel L.W., Lawrence T.S. Metabolism of 2′2′-difluoro-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
21. Trepel M., Groscurth P., Malipiero U., Gulbins E., Dichgans J., Weller M. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J. Neurooncol. 39:1998;19-32.
22. Van Meir E.G., Kikuchi T., Tada M., Li H., Diserens A.C., Wojcik B.E., Huang H.J.S., Friedmann T., de Tribolet N., Cavenee W.K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:1994;649-653.
23. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292:1998;435-445.
24. Weller M., Malipiero U.V., Aguzzi A., Reed J.C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95:1995;2633-2643.
25. Weller M., Schmidt C., Roth W., Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology. 48:1997;1704-1709.
26. Weller M., Winter S., Schmidt C., Esser P., Fontana A., Dichgans J., Groscurth P. Topoisomerase I inhibitors for human malignant glioma. Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int. J. Cancer. 73:1997;707-714.
27. Weller, M., Rieger, J., Grimmel, C., Van Meir, E.G., De Tribolet, N., Krajewski, S., Reed, J.C., von Deimling, A., Dichgans, J., 1998. Predicting chemoresistence in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer (in press).